Global Primary Biliary Cholangitis Therapeutics Market 2019-2023
SKU ID : TNV-14416347 | Publishing Date : 17-Jun-2019 | No. of pages : 131
Detailed TOC of Global Primary Biliary Cholangitis Therapeutics Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY PRODUCT
Market segmentation by product
Comparison by product
OCALIVA - Market size and forecast 2018-2023
Ursodiol - Market size and forecast 2018-2023
Others - Market size and forecast 2018-2023
Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 12: MARKET TRENDS
Strong pipeline
Increasing drug designations
Advent of regenerative therapy
PART 13: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 14: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Abbott Laboratories
Allergan Plc
Eli Lilly and Co.
Intercept Pharmaceuticals Inc.
Takeda Pharmaceutical Co. Ltd.
PART 15: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global primary biliary cholangitis therapeutics market pipeline: Overview
Exhibit 18: Global primary biliary cholangitis therapeutics market pipeline: Snapshot
Exhibit 19: Product - Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: OCALIVA - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: OCALIVA - Year-over-year growth 2019-2023 (%)
Exhibit 23: Ursodiol - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Ursodiol - Year-over-year growth 2019-2023 (%)
Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Others - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in North America
Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Europe
Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: Abbott Laboratories - Vendor overview
Exhibit 52: Abbott Laboratories - Business segments
Exhibit 53: Abbott Laboratories - Organizational developments
Exhibit 54: Abbott Laboratories - Geographic focus
Exhibit 55: Abbott Laboratories - Segment focus
Exhibit 56: Abbott Laboratories - Key offerings
Exhibit 57: Abbott Laboratories - Key customers
Exhibit 58: Allergan Plc - Vendor overview
Exhibit 59: Allergan Plc - Business segments
Exhibit 60: Allergan Plc - Organizational developments
Exhibit 61: Allergan Plc - Geographic focus
Exhibit 62: Allergan Plc - Segment focus
Exhibit 63: Allergan Plc - Key offerings
Exhibit 64: Allergan Plc - Key customers
Exhibit 65: Eli Lilly and Co. - Vendor overview
Exhibit 66: Eli Lilly and Co. - Business segments
Exhibit 67: Eli Lilly and Co. - Organizational developments
Exhibit 68: Eli Lilly and Co. - Geographic focus
Exhibit 69: Eli Lilly and Co. - Segment focus
Exhibit 70: Eli Lilly and Co. - Key offerings
Exhibit 71: Eli Lilly and Co. - Key customers
Exhibit 72: Intercept Pharmaceuticals Inc. - Vendor overview
Exhibit 73: Intercept Pharmaceuticals Inc. - Business segments
Exhibit 74: Intercept Pharmaceuticals Inc. - Organizational developments
Exhibit 75: Intercept Pharmaceuticals Inc. - Geographic focus
Exhibit 76: Intercept Pharmaceuticals Inc. - Key offerings
Exhibit 77: Intercept Pharmaceuticals Inc. - Key customers
Exhibit 78: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 79: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 83: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 84: Validation techniques employed for market sizing
Exhibit 85: Definition of market positioning of vendors
Keyplayers in Global Primary Biliary Cholangitis Therapeutics Market 2019-2023
Abbott LaboratoriesAllergan Plc
Eli Lilly and Co.
Intercept Pharmaceuticals Inc.
Takeda Pharmaceutical Co. Ltd.